We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The new Bimzelx administration and dosage is available ...

The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial ...

Bimzelx is a brand-name biologic medication used to treat plaque psoriasis and other conditions by blocking specific immune system proteins that cause inflammation. More common side effects of Bimzelx ...

(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration ...

Bimzelx (bimekizumab-bkzx) is a prescription drug used in certain adults to treat plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and ...

BIMZELX ® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Credit: UCB The new presentations allow for single administration for certain indications. The new presentations allow for single administration to treat plaque psoriasis, hidradenitis suppurativa, ...

ATLANTA, March 27, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced data for BIMZELX in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American ...

Bimzelx is prescribed for moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in ...